Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Left ventricular recovery and outcomes in patients with a durable left ventricular assist device: the EUROMACS registry.

European heart journal·2026
Same author

Peak Oxygen Uptake for Risk Stratification in Fully Magnetically Levitated Left Ventricular Assist Device Recipients.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Hemodynamic principles of arterial cannulation: Orientation, wall shear stress, turbulence, plaque destabilization, and cerebral microembolization.

Asian cardiovascular & thoracic annals·2026
Same author

Reply to 'Beyond socioeconomic status: structural determinants and strategic approaches to regional variation in left ventricular assist device utilization'.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2026
Same author

Environmental risk factors and cardiovascular health.

European heart journal·2026
Same author

Out-of-hours primary care management for patients with heart failure.

ESC heart failure·2026

Related Experiment Video

Updated: May 3, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.2K

Outcome after left ventricular assist device exchange.

Jaiel Niamat1, Faiz Ramjankhan1, Niels Van Der Kaaij1

  • 1Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, Netherlands.

European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|September 5, 2024
PubMed
Summary

Left ventricular assist device (LVAD) exchange is a viable option for patients with chronic heart failure, though complications like infections and device issues are common. Specific devices may increase risks for heart and respiratory failure post-exchange.

Keywords:
Heart failureHeartMateHeartWare ventricular assist deviceLeft ventricular assist deviceLeft ventricular assist device malfunction

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.9K

Related Experiment Videos

Last Updated: May 3, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.9K

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Medical Device Technology

Background:

  • Left ventricular assist device (LVAD) therapy is increasingly used long-term due to transplant waiting lists and destination therapy.
  • LVAD complications can necessitate device exchange, impacting patient management.
  • Understanding outcomes after LVAD exchange is crucial for optimizing patient care.

Purpose of the Study:

  • To evaluate patient outcomes following left ventricular assist device (LVAD) exchange.
  • To identify risk factors associated with short-term and long-term adverse events after LVAD exchange.
  • To assess survival rates and long-term results post-LVAD exchange.

Main Methods:

  • Retrospective analysis of patients undergoing LVAD exchange from 2010 to 2022.
  • Logistic and Cox regression analyses to determine risk factors for adverse events.
  • Kaplan-Meier estimates to evaluate survival post-exchange.

Main Results:

  • Eighty LVAD exchanges were performed in 61 patients.
  • Short-term complications included pulmonary infections (16.3%) and right heart failure (16.3%).
  • Long-term complications were exit-site infections (34.7%) and device malfunctions (25.3%).
  • HeartWare device use was linked to higher risks of right heart failure and respiratory failure.
  • One-year survival was 83%, and six-year survival was 67%.
  • At 5 years post-exchange, 25% were transplanted, 23.8% re-exchanged, and 32.5% alive without intervention.

Conclusions:

  • LVAD exchange has relatively low mortality but frequent post-operative adverse events.
  • Patients with HeartWare devices may face increased risks of right heart and respiratory failure.
  • Careful patient selection and monitoring are essential after LVAD exchange.